Managed Healthcare Executive March 18, 2025
EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.
AstraZeneca is buying EsoBiotec for up to $1 billion for the company’s in vivo CAR-T cell drugs, or therapies that reprogram immune cells directly within patients’ bodies. Analysts say the deal highlights the pharma industry’s growing interest in this technology.
Current CAR-T cell therapies have transformed the treatment landscape for certain blood cancers, but the drugs are complex and time-consuming to manufacture and carry high price tags. They also carry weeks-long post-treatment monitoring protocols and are mostly available only at major medical centers, limiting access. In vivo approaches aim to overcome these limitations and potentially extend cell therapy...
Today's Sponsors
Today's Sponsor